Crisaborole
Crisaborole, sold under the brand name Eucrisa among others, is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in adults and children.[1][2][3]
![]() | |
Clinical data | |
---|---|
Pronunciation | /juːˈkrɪsə/ yoo-KRIS-ə |
Trade names | Eucrisa, Staquis |
Other names | AN-2728 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617019 |
License data |
|
Pregnancy category |
|
Routes of administration | Topical (ointment) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.225.309 ![]() |
Chemical and physical data | |
Formula | C14H10BNO3 |
Molar mass | 251.05 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects are reactions at the application site (including burning or stinging).[3]
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known.[1][2]
Side effects
At the site of application, crisaborole may cause burning or stinging. Rarely, there may be an allergic reaction.[4]
Medical uses
In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older.[2]
In the EU, crisaborole is indicated for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.[3]
Pharmacology
Pharmacodynamics
Crisaborole is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation.[5] Chemically, crisaborole is a phenoxybenzoxaborole.[5] Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.[5]
People with atopic dermatitis produce high levels of proteins called cytokines, which can cause the inflammation of the skin seen in dermatitis.[3] Crisaborole blocks the release of certain cytokines involved in the inflammation process such as tumor necrosis factor alpha, interleukins (IL‑2, IL-4, IL-5), and interferon gamma.[3] By blocking their release, crisaborole is expected to ease the inflammation and therefore relieve symptoms of the disease.[3]
Chemistry
Crisaborole (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) is a member of the class of benzoxaboroles characterized by the presence of a boronic acid hemiester with a phenolic ether and a nitrile.[6] Crisaborole crystallizes into two polymorphs that differ in the conformation of the oxaborole ring. A cocrystal with 4,4'-bipyridine has been prepared and studied by X-ray crystallography.[7]
History
Crisaborole was developed by Anacor Pharmaceuticals for the topical treatment of psoriasis.[8][5][9] During preclinical and clinical development, crisaborole was called AN2728 and PF-06930164.[10] The drug was assumed to be potential $2bn-a-year blockbuster, when Pfizer acquired Anacor Pharmaceuticals.[11] However, the drug was commercially not successful, reaching only US$147 million in sales in 2018, and US$138 million in sales in 2019.[12]
Crisaborole was approved for use in the United States in December 2016[13][1] and for use in Canada in June 2018.[14]
The safety and efficacy of crisaborole were established in two placebo-controlled trials with a total of 1,522 participants ranging in age from two years of age to 79 years of age, with mild to moderate atopic dermatitis.[1] In both trials participants received treatment with either crisaborole or placebo twice daily for 28 days.[15] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.[15] Overall, participants receiving crisaborole achieved greater response with clear or almost clear skin after 28 days of treatment.[1][15] The trials were conducted in the US.[15]
Crisaborole was approved for use in the European Union in March 2020, for the treatment of mild to moderate atopic dermatitis.[3]
See also
- Tavaborole – a structurally related topical antifungal developed by Anacor
References
- "FDA Approves Eucrisa for Eczema" (Press release). U.S. Food and Drug Administration (FDA). 14 December 2016.
This article incorporates text from this source, which is in the public domain.
- "Eucrisa- crisaborole ointment". DailyMed. 21 April 2020. Retrieved 28 April 2020.
- "Staquis EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 28 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "PRODUCT MONOGRAPH" (PDF). Government of Canada. 7 June 2018. Archived (PDF) from the original on 7 April 2019. Retrieved 7 April 2019.
- Moustafa F, Feldman SR (May 2014). "A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology" (PDF). Dermatology Online Journal. 20 (5): 22608. PMID 24852768.
- "WHO Drug Information, Vol. 29, No. 3, 2015. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Information. p. 391. Retrieved 26 April 2016.
- Campillo-Alvarado G, Didden TD, Oburn SM, Swenson DC, MacGillivray LR (2018). "Exploration of Solid Forms of Crisaborole: Crystal Engineering Identifies Polymorphism in Commercial Sources and Facilitates Cocrystal Formation". Crystal Growth & Design. 18 (8): 4416–4419. doi:10.1021/acs.cgd.8b00375. ISSN 1528-7483.
- Nazarian R, Weinberg JM (November 2009). "AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis". Current Opinion in Investigational Drugs. 10 (11): 1236–42. PMID 19876791.
- Spreitzer H (16 August 2016). "Neue Wirkstoffe: Crisaborol". Österreichische Apotheker-Zeitung (in German) (17/2016).
- "Crisaborole". AdisInsight. Retrieved 24 July 2017.
- "Pfizer to Acquire Anacor". Pfizer (Press release). 16 May 2016. Retrieved 28 April 2020.
- "Pfizer Financial Report" (PDF). Pfizer. Retrieved 9 April 2020.
- "Eucrisa (crisaborole) Ointment". U.S. Food and Drug Administration (FDA). 23 January 2017. Retrieved 28 April 2020.
- "Eucrisa Regulatory Decision Summary". Health Canada. 23 October 2014. Archived from the original on 14 September 2019. Retrieved 14 September 2019.
- "Drug Trials Snapshot: Eucrisa". U.S. Food and Drug Administration (FDA). 14 December 2016. Retrieved 28 April 2020.
This article incorporates text from this source, which is in the public domain.
External links
- "Crisaborole". Drug Information Portal. U.S. National Library of Medicine.